報價延遲最少15分鐘:2025/03/28 08:23 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
21.51 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.89/-2.15
|
|
企業價值
1.01B
|
| 資產負債 |
|
每股賬面淨值
6.32
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/03/28 08:23 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2. |